Royalty Pharma's total assets for Q2 2024 were $17.66B, an increase of 9.46% from the previous quarter. RPRX total liabilities were $7.90B for the fiscal quarter, a 26.13% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.